Clinical Trial Update: Switching From Fondaparinux to Bivalirudin or Unfractionated Heparin in ACS Patients Undergoing PCI [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating switching from fondaparinux to either bivalirudin or unfractionated heparin in acute coronary syndrome patients undergoing percutaneous…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Syndromes

Drugs mentioned

• Bivalirudin (Angiomax) (bivalirudin)
• Fondaparinux (Arixtra) (Fondaparinux sodium)
• Unfractionated Heparin (unfractionated heparin)

Snippet

Sponsor: Medstar Health Research Institute | Conditions: Acute Coronary Syndromes | Phase 3 | Status: COMPLETED | Results posted: 2013-08-01